Success Stories: NIW Granted for Breakthrough Research in Tumor Immunology and T Cell Modulation
Client’s Testimonial:
“I am truly grateful to the North America Immigration Law Group (NAILG) for their professional and meticulous support throughout my EB-2 NIW petition process. They demonstrated a deep understanding of both immigration law and the scientific relevance of my research. What stood out most was their rigorous attention to detail—they carefully reviewed every word of my documents to ensure clarity, accuracy, and compliance. Every time I had a question, they responded promptly and professionally, which gave me great peace of mind. ”
On April 3rd, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Staff Scientist in the Field of Immunotherapy (Approval Notice).
General Field: Immunotherapy
Position at the Time of Case Filing: Staff Scientist
Country of Origin: China
State of Residence at the Time of Filing: California
Approval Notice Date: April 3rd, 2025
Processing Time: 11 months, 24 days
Case Summary:
Our client’s work in the field of immunotherapy stands at the intersection of innovation and clinical relevance. Her proposed endeavor focuses on advancing the identification of new therapeutic targets for cancer, autoimmune diseases, and chronic inflammatory conditions by leveraging high-throughput technologies such as single-cell sequencing. Through this approach, she examines T cell behavior within tumor microenvironments and the immune responses elicited by cancer treatments and vaccines.
By combining advanced immunoprofiling techniques with in vitro and in vivo immune assays, our client’s research enables the evaluation of current treatment efficacy and helps identify novel, cost-effective strategies to modulate immune responses. Her contributions support not only therapeutic innovation but also the development of more accessible treatment pathways, an outcome of clear national interest.
In recognition of the public health value of her work, she has received funding support from prominent federal agencies, including the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI). These grants reflect the significance and impact of her scientific inquiries in addressing some of the nation’s most challenging diseases.
To further her research in the United States, our client retained the North America Immigration Law Group (NAILG) to pursue a National Interest Waiver (NIW) petition. NAILG’s legal team presented a petition emphasizing the originality of her contributions and their alignment with pressing healthcare priorities. Rather than relying solely on theoretical advancements, the petition highlighted her practical impact through:
● 14 peer-reviewed journal articles, including 4 first-authored and 3 co-first-authored
● 411 total citations, marking her growing influence in the immunotherapy research community
● 20+ peer reviews, showcasing her role in advancing scientific discourse and quality assurance
The strength of her petition was further reinforced by expert support. As one recommender wrote:
“To conclude, [client]’s leadership in immunotherapy is clearly demonstrated by her commitment to the development of effective inflammatory treatments that do not compromise normal immunity. There is thus no doubt that [client] shall continue to produce additional valuable research, both driving progress in the field and bringing immense benefits to national and international concerns.”
With the NIW approved, our client is now positioned to continue her work on T cell-driven immunotherapies and immune system modulation, fields that are vital not only to biomedical progress but to national health outcomes and scientific leadership on a global scale.